NCT00547157View on ClinicalTrials.gov

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
CancerHead and Neck CancerOncologySquamous Cell Carcinoma
Interventions
DRUG

Panitumumab

Arm 2 consists of panitmumab plus RT

DRUG

Cisplatin

Cisplatin

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY